Logo image of PRE

PRENETICS GLOBAL LTD-CL A (PRE) Stock Fundamental Analysis

NASDAQ:PRE - Nasdaq - KYG722451229 - Common Stock - Currency: USD

8.49  -0.51 (-5.67%)

After market: 8.49 0 (0%)

Fundamental Rating

3

Overall PRE gets a fundamental rating of 3 out of 10. We evaluated PRE against 103 industry peers in the Health Care Providers & Services industry. The financial health of PRE is average, but there are quite some concerns on its profitability. PRE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PRE had negative earnings in the past year.
In the past 5 years PRE always reported negative net income.
In the past 5 years PRE reported 4 times negative operating cash flow.
PRE Yearly Net Income VS EBIT VS OCF VS FCFPRE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 0 -50M -100M -150M

1.2 Ratios

PRE's Return On Assets of -25.50% is on the low side compared to the rest of the industry. PRE is outperformed by 85.44% of its industry peers.
Looking at the Return On Equity, with a value of -31.41%, PRE is doing worse than 69.90% of the companies in the same industry.
Industry RankSector Rank
ROA -25.5%
ROE -31.41%
ROIC N/A
ROA(3y)-28.89%
ROA(5y)-31.4%
ROE(3y)-37.26%
ROE(5y)-47.44%
ROIC(3y)N/A
ROIC(5y)N/A
PRE Yearly ROA, ROE, ROICPRE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 -20 -40 -60 -80 -100

1.3 Margins

With a decent Gross Margin value of 42.48%, PRE is doing good in the industry, outperforming 68.93% of the companies in the same industry.
PRE's Gross Margin has been stable in the last couple of years.
PRE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 42.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.16%
GM growth 5YN/A
PRE Yearly Profit, Operating, Gross MarginsPRE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -100 -200

More info and screens

5

2. Health

2.1 Basic Checks

PRE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PRE has been increased compared to 1 year ago.
PRE has a better debt/assets ratio than last year.
PRE Yearly Shares OutstandingPRE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
PRE Yearly Total Debt VS Total AssetsPRE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 2.27 indicates that PRE is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of PRE (2.27) is comparable to the rest of the industry.
PRE has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
PRE has a Debt to Equity ratio of 0.00. This is amongst the best in the industry. PRE outperforms 84.47% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.27
ROIC/WACCN/A
WACC7.54%
PRE Yearly LT Debt VS Equity VS FCFPRE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 100M 200M 300M 400M

2.3 Liquidity

PRE has a Current Ratio of 2.37. This indicates that PRE is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 2.37, PRE belongs to the best of the industry, outperforming 82.52% of the companies in the same industry.
PRE has a Quick Ratio of 2.29. This indicates that PRE is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of PRE (2.29) is better than 82.52% of its industry peers.
Industry RankSector Rank
Current Ratio 2.37
Quick Ratio 2.29
PRE Yearly Current Assets VS Current LiabilitesPRE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 85.17% over the past year.
The Revenue for PRE has decreased by -92.12% in the past year. This is quite bad
The Revenue for PRE have been decreasing by -30.65% on average. This is quite bad
EPS 1Y (TTM)85.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.47%
Revenue 1Y (TTM)-92.12%
Revenue growth 3Y-30.65%
Revenue growth 5YN/A
Sales Q2Q%93.22%

3.2 Future

The Earnings Per Share is expected to grow by 24.41% on average over the next years. This is a very strong growth
Based on estimates for the next years, PRE will show a very strong growth in Revenue. The Revenue will grow by 22.44% on average per year.
EPS Next Y20.64%
EPS Next 2Y22.47%
EPS Next 3Y24.41%
EPS Next 5YN/A
Revenue Next Year-56.61%
Revenue Next 2Y0.18%
Revenue Next 3Y22.44%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PRE Yearly Revenue VS EstimatesPRE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M 200M 250M
PRE Yearly EPS VS EstimatesPRE Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PRE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PRE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRE Price Earnings VS Forward Price EarningsPRE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRE Per share dataPRE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

PRE's earnings are expected to grow with 24.41% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.47%
EPS Next 3Y24.41%

More info and screens

0

5. Dividend

5.1 Amount

PRE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PRENETICS GLOBAL LTD-CL A

NASDAQ:PRE (6/27/2025, 8:00:00 PM)

After market: 8.49 0 (0%)

8.49

-0.51 (-5.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)04-30 2025-04-30/amc
Earnings (Next)N/A N/A
Inst Owners12.63%
Inst Owner Change0.91%
Ins Owners14.52%
Ins Owner Change0%
Market Cap110.62M
Analysts80
Price Target14.28 (68.2%)
Short Float %0.38%
Short Ratio1.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.43%
Min EPS beat(2)-107.26%
Max EPS beat(2)90.4%
EPS beat(4)1
Avg EPS beat(4)-32.6%
Min EPS beat(4)-107.26%
Max EPS beat(4)90.4%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-71.46%
Min Revenue beat(2)-73.45%
Max Revenue beat(2)-69.46%
Revenue beat(4)0
Avg Revenue beat(4)-62.2%
Min Revenue beat(4)-78.3%
Max Revenue beat(4)-27.58%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)55.56%
PT rev (3m)55.56%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.28
P/FCF N/A
P/OCF N/A
P/B 0.54
P/tB 0.68
EV/EBITDA N/A
EPS(TTM)-4.2
EYN/A
EPS(NY)-2.1
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS2.59
BVpS15.84
TBVpS12.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.5%
ROE -31.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 42.48%
FCFM N/A
ROA(3y)-28.89%
ROA(5y)-31.4%
ROE(3y)-37.26%
ROE(5y)-47.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.16%
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.37
Quick Ratio 2.29
Altman-Z 2.27
F-ScoreN/A
WACC7.54%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.47%
EPS Next Y20.64%
EPS Next 2Y22.47%
EPS Next 3Y24.41%
EPS Next 5YN/A
Revenue 1Y (TTM)-92.12%
Revenue growth 3Y-30.65%
Revenue growth 5YN/A
Sales Q2Q%93.22%
Revenue Next Year-56.61%
Revenue Next 2Y0.18%
Revenue Next 3Y22.44%
Revenue Next 5YN/A
EBIT growth 1Y-19586.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.43%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A